Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source

Stem Cells and Development

Volumn 23, Issue 11, 2014, Pages 1258-1265

  Carrade Holt, Danielle D ^a   Wood, Joshua A ^a   Granick, Jennifer L ^a,b   Walker, Naomi J ^a   Clark, Kaitlin C ^a   Borjesson, Dori L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL FUNCTION; CELL PROLIFERATION; CELLULAR SECRETION; EQUIDAE; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; ADIPOSE TISSUE; ANIMAL; BONE MARROW CELL; CELL SEPARATION; COCULTURE; CYTOLOGY; DRUG EFFECTS; FETUS BLOOD; HORSE; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; BONE MARROW CELLS; CELL PROLIFERATION; CELL SEPARATION; COCULTURE TECHNIQUES; FETAL BLOOD; HORSES; INTERLEUKIN-6; MESENCHYMAL STROMAL CELLS; NITRIC OXIDE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84901299559     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0537     Document Type: Article

References (45)

1. Jiang Y, BN Jahagirdar, RL Reinhardt, RE Schwartz, CD Keene, XR Ortiz-Gonzalez, M Reyes, T Lenvik, T Lund, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49.
2. Dominici M, K Le Blanc, I Mueller, I Slaper-Cortenbach, F Marini, D Krause, R Deans, A Keating, D Prockop and E Horwitz. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
3. Voswinkel J, S Francois, J-M Simon, M Benderitter, N-C Gorin, M Mohty, L Fouillard and A Chapel. (2013). Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review. Clin Rev Allergy Immunol 45:180-192.
4. Kern S, H Eichler, J Stoeve, H Klüter and K Bieback. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294-1301.
5. Troyer DL and ML Weiss. (2008). Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 26:591-599.
6. Schuh EM, MS Friedman, DD Carrade, J Li, D Heeke, SM Oyserman, LD Galuppo, DJ Lara, NJ Walker, et al. (2009). Identification of variables that optimize isolation and culture of multipotent mesenchymal stem cells from equine umbilical-cord blood. Am J Vet Res 70:1526-1535.
7. Vidal MA, GE Kilroy, MJ Lopez, JR Johnson, RM Moore and JM Gimble. (2007). Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells. Vet Surg 36:613-622.
8. Toupadakis CA, A Wong, DC Genetos, WK Cheung, DL Borjesson, GL Ferraro, LD Galuppo, JK Leach, SD Owens and CE Yellowley. (2010). Comparison of the osteogenic potential of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue. Am J Vet Res 71:1237-1245.
9. Smith RKW, M Korda, GW Blunn and AE Goodship. (2003). Isolation and implantation of autologous equine mesenchymal stem cells from bone marrow into the superficial digital flexor tendon as a potential novel treatment. Equine Vet J 35:99-102.
10. Vidal MA, SO Robinson, MJ Lopez, DB Paulsen, O Borkhsenious, JR Johnson, RM Moore and JM Gimble. (2008). Comparison of chondrogenic potential in equine mesenchymal stromal cells derived from adipose tissue and bone marrow. Vet Surg 37:713-724.
11. Barry FP and JM Murphy. (2004). Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 36:568-584.
12. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, S Grisanti and AM Gianni. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843.
13. Barminko J, A Gray, T Maguire, R Schloss and ML Yarmush. (2013). Mesenchymal stromal cell mechanisms of immunomodulation and homing. In: Mesenchymal Stem Cell Therapy. LG Chase, MC Vemuri, and K Turksen, eds. Humana Press, New York, pp 15-38.
14. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
15. Carrade DD and DL Borjesson. (2013). Immunomodulation by mesenchymal stem cells in veterinary species. Comp Med 63:1-11.
16. Carrade DD, MW Lame, MS Kent, KC Clark, NJ Walker and DL Borjesson. (2012). Comparative analysis of the immunomodulatory properties of equine adult-derived mesenchymal stem cells. Cell Med 4:1-11.
17. Rasmusson I, O Ringdén, B Sundberg and K Le Blanc. (2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 305:33-41.
18. Nauta AJ and WE Fibbe. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506.
19. Sato K, K Ozaki, I Oh, A Meguro, K Hatanaka, T Nagai, K Muroi and K Ozawa. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228-234.
20. Glennie S, I Soeiro, PJ Dyson, EW-F Lam and F Dazzi. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105:2821-2827.
21. Plumas J, L Chaperot, MJ Richard, JP Molens, JC Bensa and MC Favrot. (2005). Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19:1597-1604.
22. Bartholomew S, SD Owens, GL Ferraro, DD Carrade, DJ Lara, FA Librach, DL Borjesson and LD Galuppo. (2009). Collection of equine cord blood and placental tissues in 40 thoroughbred mares. Equine Vet J 41:724-728.
23. Carrade DD, SD Owens, LD Galuppo, MA Vidal, GL Ferraro, F Librach, S Buerchler, MS Friedman, NJ Walker and DL Borjesson. (2010). Clinicopathologic findings following intra-articular injection of autologous and allogeneic placentally derived equine mesenchymal stem cells in horses. Cytotherapy 13:419-430.
24. Vidal M, NJ Walker, E Napoli and DL Borjesson. (2011). Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue and umbilical cord tissue. Stem Cells Dev 21:273-283.
25. Frisbie DD, F Al-Sobayil, RC Billinghurst, CE Kawcak and CW McIlwraith. (2008). Changes in synovial fluid and serum biomarkers with exercise and early osteoarthritis in horses. Osteoarthritis Cartilage 16:1196-1204.
26. McFarlane D and TC Holbrook. (2008). Cytokine dysregulation in aged horses and horses with pituitary pars intermedia dysfunction. J Vet Intern Med 22:436-442.
27. Burton AB, B Wagner, HN Erb and DM Ainsworth. (2009). Serum interleukin-6 (IL-6) and IL-10 concentrations in normal and septic neonatal foals. Vet Immunol Immunopathol 132:122-128.
28. Goodman WA, AB Young, TS McCormick, KD Cooper and AD Levine. (2011). Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol 186:3336-3345.
29. Kimura A and T Kishimoto. (2010). IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40:1830-1835.
30. Wang D, YR Ji, K Chen, WT Du, ZX Yang, ZB Han, Y Chi, L Liang, F Bayard and ZC Han. (2012). IL-6 production stimulated by CD14 + monocytes-paracrined IL-1b does not contribute to the immunosuppressive activity of human umbilical cord mesenchymal stem cells. Cell Physiol Biochem 29:551-560.
31. Akira S, T Hirano, T Taga and T Kishimoto. (1990). Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 4:2860-2867.
32. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, RC Zhao and Y Shi. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines andnitric oxide. Cell Stem Cell 2:141-150.
33. Ghannam S, C Bouffi, F Djouad, C Jorgensen and D Noel. (2010). Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 1:2.
34. Wink DA, HB Hines, RYS Cheng, CH Switzer, W Flores- Santana, MP Vitek, LA Ridnour and CA Colton. (2011). Nitric oxide and redox mechanisms in the immune response. J Leuk Biol 89:873-891.
35. Hsu W-T, C-H Lin, B-L Chiang, H-Y Jui, KK-Y Wu and C-M Lee. (2013). Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10 + IFN-g + CD4 + regulatory T cells to control transplant arteriosclerosis. J Immunol 190:2372-2380.
36. Chen K, D Wang, WT Du, Z-B Han, H Ren, Y Chi, SG Yang, D Zhu, F Bayard and ZC Han. (2010). Human umbilical cord mesenchymal stem cells hUC-MSCs exert immunosuppressive activities through a PGE2-dependent mechanism. Clin Immunol 135:448-458.
37. Schoenborn JR and CB Wilson. (2007). Regulation of interferon-g during innate and adaptive immune responses. Advances in Immunology 96:41-101.
38. Szodoray P, G Papp, IF Horvath, S Barath, S Sipka, B Nakken and M Zeher. (2009). Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol 157:343-349.
39. Zappia E, S Casazza, E Pedemonte, F Benvenuto, I Bonanni, E Gerdoni, D Giunti, A Ceravolo, F Cazzanti, et al. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106:1755-1761.
40. Ramasamy R, H Fazekasova, EW-F Lam, I Soeiro, G Lombardi and F Dazzi. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83: 71-76.
41. Groux H, M Bigler, JE de Vries and MG Roncarolo. (1996). Interleukin-10 induces a long-term antigen-specific anergic state in human CD4 + T cells. J Exp Med 184: 19-29.
42. Pellegrini JD, AK De, K Kodys, JC Puyana, RK Furse and C Miller-Graziano. (2000). Relationships between T lymphocyte apoptosis and anergy following trauma. J Surg Res 88:200-206.
43. Zhang Z, J Fu, X Xu, S Wang, R Xu, M Zhao, W Nie, X Wang, J Zhang, et al. (2013). Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS 27:1283-1293.
44. Gougeon ML, H Lecoeur, A Dulioust, MG Enouf, M Crouvoiser, C Goujard, T Debord and L Montagnier. (1996). Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 156: 3509-3520.
45. Massanella M, M Curriu, J Carrillo, E Gómez, J Puig, J Navarro, J Dalmau, J Martínez-Picado, M Crespo, et al. (2013). Assessing main death pathways in T lymphocytes from HIV infected individuals. Cytom Part A 83A:648-658.